Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  ORGAN AND TISSUE TRANSPLANTATION
A Global Strategic Business Report

This report analyzes the worldwide markets for Organ And Tissue Transplantation by Number of Procedures. The specific product segments analyzed for the global and other markets (except the US) by Organ Type are Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine. The US market has been specifically analyzed both by Organ & Tissue Transplantation market, and Bone Graft Transplantation market. The report analyzes the US market for Organ & Tissue Transplantation both by Organ Type (Heart, Kidneys, Liver, Pancreas, and Lungs) and by Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts). Bone Graft Transplantation market in the US is analyzed both by Graft Type (Autologous Graft, Allograft, and Other Materials); and by Application Type (General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report provides separate comprehensive analytics for the US, Canada, Europe, Asia, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2003 through 2012. The report profiles 77 companies including many key and niche players worldwide such as Abiomed Inc., Arbios Systems, Inc., CryoLife, Inc., Exactech, Inc., Fresenius Medical Care AG & Co. KGaA, Forticell Bioscience, Inc., Gambro AB, Genzyme Corporation, Jarvik Heart, Inc., LifeCell Corporation, Medtronic, Inc., MicroMed Cardiovascular, Inc., Organogenesis, Inc., SynCardia Systems, Terumo Corporation, Thoratec Corporation, Ventracor Limited, and WorldHeart Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1572  PAGES:    414
PRICE:    $4450  DATE:       March 2008
COMPANIES:  77  MARKET DATA TABLES:   205
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  ORGAN AND TISSUE TRANSPLANTATION (Complete Report) Pages : 414   | $4450
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS6$100
   Study Reliability and Reporting Limitations...I-1  
   Disclaimers...I-2
Data Interpretation & Reporting Level...I-2
  
   Quantitative Techniques & Analytics...I-3
Product Definitions and Scope of Study...I-3
Tissue and Organ Transplantation...I-3
  
   Bone Graft Transplantation...I-4
Product Definitions...I-4
Organ Transplantation...I-4
Heart Transplantation...I-4
Kidney Transplantation...I-4
Liver Transplantation...I-4
  
   Pancreas Transplantation...I-5
Small Intestine Transplantation...I-5
Lungs...I-5
Tissue Transplantation...I-5
Corneal Transplantation...I-5
Blood Stem Cell Transplantation...I-5
  
   Bone Marrow Transplantation...I-6
Heart Valves Transplantation...I-6
  
II. EXECUTIVE SUMMARY76$2350
  1. Introduction...II-11 $100  
   Introduction...II-1
1$100
  2. Market Overview...II-22 $200  
   Current and Future Analysis...II-2
Demand and Supply Imbalance...II-2
Cardiac Arrest Death Patients – The Untapped Potential Donors...II-2
Transplantation Expenses...II-2
2$200
  3. Market Trends...II-43 $300  
   Living Donor Organs on the Rise...II-4
Combined Organ Transplantation – Gaining Attention...II-4
Awareness Programs and Education to Address Organ shortage...II-4
Increasing Consent Rates – A Key Factor...II-4
Transplant Tourism – Creating Brighter Avenues...II-4
1$100
   Alliances to Play a Key Role...II-5
Graying Population and Chronic Diseases Surge Need for Transplants...II-5
Fetal Tissue for Bionic Devices – Assuming Importance...II-5
2$200
  4. Major Issues Impacting Transplantation Market...II-72 $200  
   Organ Rejection – A Major Barrier to Transplantation...II-7
Scarcity of Donor Organs – A Stumbling Block in Organ Transplantation...II-7
Other Issues for Organ Transplantation...II-7
Ethical Concerns in Transplants...II-7
1$100
   Bioethical Issues Hindering Organ Donation Process...II-8
Lack of Requisite Expertise – Hindering Implantation Process...II-8
1$100
  5. Product Overview...II-925 $1500  
   Tissue and Organ Transplantation...II-9
Organ Transplantation...II-9
Heart Transplantation...II-9
1$100
   Heart Diseases and Disorders...II-10
Post Operative Complications and Consequences of Heart Transplants...II-10
Bleeding...II-10
Infection...II-10
Arrythymia...II-10
Heart Attack...II-10
1$100
   Coronary Artery Disease...II-11
Respiratory Dysfunction...II-11
Renal Dysfunction...II-11
Graft Rejection and Dysfunction...II-11
Death...II-11
Kidney Transplantation...II-11
1$100
   Kidney Disorders and Diseases...II-12
Donor Evaluation...II-12
Waiting List...II-12
Surgery/Post-Operation...II-12
Post-Operative Supervision and Issues...II-12
1$100
   Liver Transplantation...II-13
Liver Disorders and Diseases...II-13
1$100
   Pancreas Transplantation...II-14
Post Operative Complications and Consequences of Pancreas Transplants...II-14
1$100
   Small Intestine Transplantation...II-15
Intestine Disorders and Diseases...II-15
Heart-and-Lung Transplantation...II-15
Lung Transplantation...II-15
1$100
   Lung Diseases and Disorders...II-16
Lung Patients Survival Statistics...II-16
Tissue Transplantation...II-16
Types of Grafts...II-16
Autograft...II-16
Allograft / Homograft...II-16
1$100
   Transplant Tolerance...II-17
Isograft...II-17
Xenograft...II-17
1$100
   Corneal Transplantation...II-18
Penetrating Keratoplasty...II-18
Lamellar (Non-Penetrating) Keratoplasty...II-18
1$100
   Aftercare...II-19
Risks Associated with Corneal Transplants...II-19
Transplantation Outcomes...II-19
Morbidity and Mortality Rates...II-19
Alternatives...II-19
1$100
   Blood Stem Cells...II-20
Peripheral Blood Stem Cell Transplant...II-20
Umbilical Cord Blood Stem Cell Transplant...II-20
Bone Marrow and Hematopoietic Stem Cells...II-20
Bone and Tissue Transplantation...II-20
1$100
   Bone Marrow Transplants...II-21
Stem Cell Therapy...II-21
1$100
   Human Heart Valves...II-22
Atrioventricular Valves...II-22
Mitral Valve...II-22
Tricuspid Valve...II-22
Semilunar Valves...II-22
Aortic Valve...II-22
1$100
   Pulmonic Valve...II-23
Pathology of Valves...II-23
Prosthetic Heart Valves...II-23
Prosthetic Mechanical Valve...II-23
1$100
   Advantages...II-24
Disadvantages...II-24
Prosthetic Biologic Valve...II-24
Advantages...II-24
1$100
   Disadvantages...II-25
Fetal Cells...II-25
Fetal Tissue for Transplantation...II-25
Storage Duration Time...II-25
1$100
   Storage Time Period for Organs and Tissues...II-26
Cold Ischemia Time...II-26
Transplantation Immunology...II-26
Acute Cellular Rejection...II-26
Chronic Rejection...II-26
1$100
   Post Transplant Observations...II-27
Types of Donors...II-27
Alive Donors...II-27
Related Donors...II-27
Good Samaritans...II-27
Rewarded/Forced Donors...II-27
Deceased Donors...II-27
1$100
   Directed / Allocated...II-28
Organs and Tissues Transplanted by Type of Donor...II-28
Organ/Tissue Donation and Eligibility Criteria...II-28
1$100
   Factors Considered for Matching Recipients to Donor Organs...II-29
Testing ...II-29
Blood Typing...II-29
Tissue Typing...II-29
Histocompatibility – A Major Barrier for Organ Transplantation...II-29
1$100
   Transplantation – Safety Requirements...II-301$100
   Waiting List...II-31
Active Waiting List Patients...II-31
Inactive Waiting List Patients...II-31
History ...II-31
2$200
   Major Milestones in Organ Transplantation...II-33
1$100
  6. Artificial Organs...II-348 $500  
   Artificial Organs Revolutionize Medical Technology Industry...II-34
Artificial Organs...II-34
Categorization of Artificial Organs...II-34
External Artificial Organs...II-34
1$100
   Internal or Implantable Artificial Devices...II-35
Artificial Heart...II-35
Total Artificial Heart (TAH)...II-35
Ventricle Assist Device (VAD)...II-35
Right Ventricular Assist Systems (RVAS)...II-35
Left Ventricular Assist Systems (LVAS)...II-35
1$100
   Various Ventricle Assist Devices...II-36
Artificial Kidney (Dialyzer)...II-36
1$100
   Limitations of Artificial Kidney...II-37
Artificial Liver...II-37
Various Liver Assist Devices...II-37
Categorization of Liver Devices...II-37
1$100
   Mechanical Systems...II-38
Bio-Artificial Systems...II-38
Artificial Pancreas...II-38
Artificial Lungs (Oxygenator)...II-38
Types of Artificial Lung...II-38
1$100
   Artificial Cornea...II-39
Keratoprostheses...II-39
Tissue Engineered Corneas...II-39
Artificial Skin/Skin Replacement Products...II-39
AlloDerm Regenerative Tissue Matrix...II-39
Apligraf...II-39
Cymetra Micronized AlloDerm Tissue...II-39
Dermagraft...II-39
1$100
   Epicel ...II-40
Integra Products...II-40
OrCel ...II-40
TransCyte...II-40
Core Competitive Factors...II-40
1$100
   Market Outlook for Artificial Organs...II-41
1$100
  7. Preservation Solutions & Immunosuppressant Drugs...II-426 $400  
   Organ Preservation Solutions...II-42
Celsior Solution...II-42
Collins Solution...II-42
Euro Collins Solution...II-42
Custodiolฎ HTK Solution...II-42
Hypothermosol...II-42
ViaSpan...II-42
1$100
   Immunosuppressant Drugs...II-43
Antibody Products for Treatment of Organ Transplant Rejection...II-43
Antithymocyte Globulin...II-43
ATGAM...II-43
Campath/MabCampath...II-43
1$100
   Thymoglobulin...II-44
Therapeutic Antibody Products...II-44
Antiproliferative Agents...II-44
Azathioprine...II-44
CellCept...II-44
Certican...II-44
Myfortic...II-44
Calcineurin Inhibitors...II-44
1$100
   Cyclosporine...II-45
Gengraf...II-45
Neoral...II-45
Pulminiq...II-45
Tacrolimus...II-45
Prograf...II-45
TOR Inhibitors...II-45
1$100
   Side Effects of Immunosuppression Therapy...II-46
Select Immunosuppressant Drug Players...II-46
Astellas Pharma US, Inc., (USA)...II-46
F.Hoffmann-La Roche Ltd (Switzerland)...II-46
Novartis AG (Switzerland)...II-46
1$100
   Wyeth (USA)...II-47
1$100
  8. Regulatory Environment...II-484 $400  
   Transplant Center...II-48
Organ Procurement Organization (OPO)...II-48
Health Resources and Services Administration (HRSA)...II-48
Division of Transplantation (DoT)...II-48
United Network for Organ Sharing (UNOS)...II-48
Organ Procurement and Transplantation Network (OPTN)...II-48
University Renal Research and Education Association (URREA)...II-48
1$100
   Scientific Registry of Transplant Recipients (SRTR)...II-49
Funding Sources...II-49
Patient Education and Advocacy Organizations...II-49
1$100
   Legal Framework for Transplantation...II-50
Legislation Covering Organ Transplant...II-50
Organ Transplantation and Ethics...II-50
1$100
   Regulations Governing Artificial Organs...II-51
1$100
  9. Product Development/Innovations...II-521 $100  
   Pluristem Develops New Cell Graft for Cancer Patients...II-52
CryoLife Develops Cryopreserved Orthopaedic Tissues Implants...II-52
Japanese Innovators Develop New Prognostic Scoring Model for Liver Transplants...II-52
EUREKA project E! 2674 MIDAS Develops New Test to Improve Graft Survival...II-52
1$100
  10. Recent Industry Activity...II-5310 $700  
   St. Jude Medical’s Heart Valve Obtains US FDA Approval...II-53
Zimmer and Tutogen Expand Distribution Partnership...II-53
Leman Cardiovascular Acquires Hancock Jaffe Laboratories...II-53
Nabi Acquires Commercialization Rights of ATG-Fresenius S for North America...II-53
1$100
   Cytopia and Novartis Ink Research Collaboration and Global License Agreement...II-54
ZLB Behring Inks Agreement with MedImmune...II-54
Japanese Team To Perform Liver Transplants in Hyderabad...II-54
Nabi Bags Approval for HB Intravenous in Liver Transplant Patients...II-54
Schering-Plough Announces PROTECT study Initiation...II-54
1$100
   Allegheny General Hospital To Establish Adult Liver Transplantation Center in
  Oakland...II-55
Global Hospitals to Setup an Organ Transplant Center in Kolkata...II-55
GCC to Establish Organ Transplant Center...II-55
Delhi-Based Hospital Offers Help in Setting Up of Liver Transplant Center in
  Lahore...II-55
Kaiser To Shut Down Kidney Transplant Center...II-55
1$100
   Abiomed Obtains FDA Approval for Selling Artificial Hearts...II-56
Astellas Bags FDA Approval to Use Prograf in Heart Transplant Patients...II-56
New York State Department of Health Approves Program for Kidney Transplant for Queen’s
  Community...II-56
National Heart Institute Conducts First Double Lung Transplant in Malaysia...II-56
The Netherlands Obtains Orphan Drug Designations for Treatment of DGF...II-56
Papworth Transplants First Beating Human Heart in the UK...II-56
1$100
   Enzon to Return ATG-Fresenius S Rights to Fresenius Biotech...II-57
Schering-Plough to Conduct ‘PROTECT’ Study...II-57
Community Tissue Services Selects NOVA 2200 Supercritical Carbon Dioxide Sterilization
  Technology...II-57
1$100
   CryoLife Inks Agreement with The Magdi Yacoub Institute to Enhance Xenografts in Human
  Transplantation...II-58
ReGen Inks Exclusive Marketing Deals with Polymedic and Xmedica...II-58
University of California-Irvine Announces Closure of Liver-Transplantation
  Program...II-58
1$100
   Swedish Health Services Bags Approval for Liver Transplant Program...II-59
New Organ Transplant Research Center in South Korea...II-59
Child Lung Transplant Unit to be opened in Melbourne Hospital...II-59
Narayana Hrudayalaya Health City Establishes Exclusive Organ Transplant
  Hospital...II-59
Liver Transplant Facility in Delhi Region...II-59
First Liver Transplant Research Institute in China...II-59
PIMS to establish Liver Transplant Unit...II-59
1$100
   Liver Transplant Programme in Pakistan...II-60
Isotechnika Gains FDA Approval...II-60
FDA Offers Approval for Brain Stem Cell Transplant Trial ...II-60
Methodist Specialty and Transplant Hospital Gains Approval to Execute Liver
  Transplants...II-60
Cubist Pharmaceuticals Enters into Licensing Agreement with XTL
  Biopharmaceuticals...II-60
1$100
   Jackson Memorial Receives Approval from the U.S. Centers for Medicare and Medicaid
  Services...II-61
Royal Perth Hospital to Open Lung Transplant Unit in Perth...II-61
Mater Hospital Opens Lung Transplant Unit in Dublin...II-61
Genzyme Makes a Synergistic Purchase of Ilex Oncology...II-61
1$100
   NIAID Sets Up Clinical Consortium to Enhance Organ Transplants Success...II-62
Chiron files NDA for Pulminiq Inhalation Solution...II-62
Roche Acquires IL-15 Antagonist...II-62
Genzyme Completes Acquisition of SangStat...II-62
1$100
  11. Focus on Select Global Players...II-637 $500  
   Abiomed Inc (USA)...II-63
Arbios Systems, Inc. (USA)...II-63
1$100
   CryoLife, Inc.(USA)...II-64
Exactech, Inc. (USA)...II-64
Fresenius Medical Care AG & Co. KGaA (Germany)...II-64
1$100
   Forticell Bioscience, Inc. (USA)...II-65
Gambro AB (Sweden)...II-65
Genzyme Corporation (USA)...II-65
1$100
   Jarvik Heart, Inc. (USA)...II-66
LifeCell Corporation (USA)...II-66
1$100
   Medtronic, Inc. (USA)...II-67
MicroMed Cardiovascular, Inc. (USA)...II-67
Organogenesis, Inc. (USA)...II-67
1$100
   SynCardia Systems (USA)...II-68
Terumo Corporation (Japan)...II-68
Thoratec Corporation (USA)...II-68
1$100
   Ventracor Limited (Australia)...II-69
WorldHeart Corporation (USA)...II-69
1$100
  12. Global Market Perspective...II-70   
   Table 1: World Recent Past, Current & Future Market Analysis for Organ Transplantation by Geographic Region – US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...II-70

Table 2: World 10-Year Perspective for Organ Transplantation by Geographic Region – Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...II-70
1$350
   Table 3: World Recent Past, Current & Future Market Analysis for Heart Transplantation by Geographic Region – US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...II-71

Table 4: World 10-Year Perspective for Heart Transplantation by Geographic Region – Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...II-71
1$350
   Table 5: World Recent Past, Current & Future Market Analysis for Kidney Transplantation by Geographic Region – US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...II-72

Table 6: World 10-Year Perspective for Kidney Transplantation by Geographic Region – Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...II-72
1$350
   Table 7: World Recent Past, Current & Future Market Analysis for Liver Transplantation by Geographic Region – US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...II-73

Table 8: World 10-Year Perspective for Liver Transplantation by Geographic Region – Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...II-73
1$350
   Table 9: World Recent Past, Current & Future Market Analysis for Pancreas Transplantation by Geographic Region – US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...II-74

Table 10: World 10-Year Perspective for PancreasTransplantation by Geographic Region – Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...II-74
1$350
   Table 11: World Recent Past, Current & Future Market Analysis for Lung Transplantation by Geographic Region – US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...II-75

Table 12: World 10-Year Perspective for Lung Transplantation by Geographic Region – Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...II-75
1$350
   Table 13: World Recent Past, Current & Future Market Analysis for Corneal Transplantation by Geographic Region – US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...II-76

Table 14: World 10-Year Perspective for Corneal Transplantation by Geographic Region – Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...II-76
1$350
III. MARKET71$2150
  1. The United States...III-144 $1925  
   A. Market Analysis...III-1
Current and Future Analysis...III-1
Analysis by Value Sales...III-1
Liver Transplantation Sustains Dominance...III-1
Skin Grafts Take the Largest Chunk...III-1
Analysis by Number of Procedures...III-1
Intestine – Fastest Growing Segment...III-1
1$75
   Skin Grafts – Largest and Fastest Growing Tissue Segment...III-2
Bone Graft Procedure Volume by Graft Type and Application...III-2
US Organ Transplant Facts and Figures...III-2
1$75
   Number of Organ Transplants Witnesses Phenomenal Surge-2004...III-3
Increasing Organ Donations in New Jersey...III-3
Innovative Means of Organ Procurement to Increase Organ Donations...III-3
A New Technique to Enhance and Extend Kidney Transplants...III-3
1$75
   California Stands Up Against Insurance on HIV Patients’ Transplantation...III-4
Awareness Programs to Address Shortage of Minority Donors...III-4
Organs and Tissues on A Recovery Spree...III-4
1$75
   Unexamined Human Tissue Transplants – A Major Threat...III-5
Defective Medical Implants – A Health Hazard...III-5
Eye Infections from Usage of MoistureLoc Leads to Corneal Transplants...III-5
Sources of Donor Organs...III-5
1$75
   Table 15: US Kidney Donations by Donor Type - Cadaveric and Living for Years 2000 through 2005 (includes corresponding Graph/Chart)...III-6

Table 16: US Liver Donations by Donor Type - Cadaveric and Living for Years 2000 through 2005 (includes corresponding Graph/Chart)...III-6

Table 17: US Heart Donations by Cadaveric Donor Type for Years 2000 through 2005 (includes corresponding Graph/Chart)...III-6
1$200
   Table 18: US Lung Donations by Donor Type - Cadaveric and Living for Years 2000 through 2005 (includes corresponding Graph/Chart)...III-7

Table 19: US Pancreas Donations by Donor Type - Cadaveric and Living for Years 2000 through 2005 (includes corresponding Graph/Chart)...III-7

Table 20: US Intestine Donations by Donor Type - Cadaveric and Living for Years 2000 through 2005 (includes corresponding Graph/Chart)...III-7
1$200
   Lung Transplantation...III-8
Lung Transplant Death Rates...III-8
Heart-Lung Transplantation...III-8
1$75
   Incidence of Organ Transplants...III-9
Table 21: Incidence of Organ Transplant Type for Kidney, Liver, Heart, Lung, Pancreas, Intestine, and Heart-Lung Transplants per 1 Million Population in the US for the Year 2000 through 2005 (includes corresponding Graph/Chart)...III-9

Table 22: Incidence of Organ Transplants (Kidney, Liver, Heart, Lung, Pancreas, Intestine, and Heart-Lung) per 1 Million Population in the US by Recipient Race (White, African American, Asian, Hispanic, and Other) for 2005 (includes corresponding Graph/Chart)...III-9
1$200
   Table 23: Incidence of Organ Transplants (Kidney, Liver, Heart, Lung, Pancreas, Intestine, and Heart-Lung) per 1 Million Population in the US by Recipient Gender (Male, and Female) for 2005 (includes corresponding Graph/Chart)...III-10

Table 24: Incidence of Organ Transplants (Kidney, Liver, Heart, Lung, Pancreas, Intestine, and Heart-Lung) per 1 Million Population in the US by Recipient Age (65+ Years, 50-64 Years, 35-49 Years, 18-34 Years, 11-17 Years, 6-10 Years, 1-5 Years, <1 Year) for 2005 (includes corresponding Graph/Chart)...III-10
1$200
   Waiting List...III-11
Table 25: Waiting List of Patients As of July 2007 (includes corresponding Graph/Chart)...III-11

Table 26: Waiting List of Active and Inactive Patients for Years 2004 & 2005 (includes corresponding Graph/Chart)...III-11
1$200
   Waiting List for Heart Transplants...III-12
Table 27: Waiting List of Active Patients for Heart for Years 2000 to 2005 (includes corresponding Graph/Chart)...III-12
Categorized by Diseases...III-12
Categorized by Age...III-12
Categorized by Race...III-12
Death Rates on Waiting List...III-12
1$200
   Kidney Transplantation Waiting List...III-13
Categorized by Age...III-13
Categorized by Race...III-13
Waiting List for Liver Transplants...III-13
Categorized by Age...III-13
Categorized by Race...III-13
Categorized by Gender...III-13
1$75
   Categorized by Diseases...III-14
Categorized by Re-Transplant Necessity...III-14
Death Rates on Waiting List...III-14
Pancreas Transplant Waiting List...III-14
Simultaneous Pancreas Kidney Transplantation Waiting List...III-14
Pancreas After Kidney and Pancreas Transplant Alone Transplant Waiting
  List...III-14
Waiting List for Lung Transplants...III-14
Categorized by Age...III-14
1$75
   Categorized by Primary Diagnoses...III-15
Categorized by Gender and Ethnic Makeup...III-15
Waiting Time for Lung Transplant...III-15
Annual Death Rates...III-15
Waiting List for Intestine Transplants...III-15
1$75
   Death Rates on Waiting List...III-16
Patient Survival Rate...III-16
Table 28: Patient Survival Percent by Organ Type for 1-Year and 5-Years (includes corresponding Graph/Chart)...III-16
1$200
   Annual Death Rate of Kidney Recipients...III-17
Pancreas Patient Survival Rate...III-17
Pancreas Graft Survival Rate...III-17
Immunosuppression Therapy...III-17
Immunosuppression Therapy for Heart Transplant Recipients...III-17
Table 29: Usage Rates of Major Immunosuppressants in 2004 (includes corresponding Graph/Chart)...III-17
1$200
   Immunosuppression Therapy for Kidney Transplant Recipients...III-18
Immunosuppression Therapy for Pancreas Transplants...III-18
Immunosuppression Therapy for Lung Transplant Recipients...III-18
Table 30: Usage Rates of Induction Therapies in 2005 (includes corresponding Graph/Chart)...III-18
1$200
   Immunosuppression Therapy Following Bone Marrow Transplantation...III-19
Table 31: US Recent Past, Current & Future Market Analysis for Immunosuppressive Drug Therapy Following Bone Marrow Transplantation by Category – For GVHD and Maintenance Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2012 (includes corresponding Graph/Chart)...III-19
Immunosuppression Therapy Following Blood Stem Cell Transplantation...III-19
1$200
   Table 32: US Recent Past, Current & Future Market Analysis for Immunosuppressive Drug Therapy Following Blood Stem Cell Transplantation by Category – For GVHD and Maintenance Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2012 (includes corresponding Graph/Chart)...III-20
United Network for Organ Sharing...III-20
The American Association of Tissue Banks (AATB)...III-20
1$200
   Accredited Banks from Select US States...III-211$75
   Eye Banks from Select US States...III-221$75
   Number of Transplant Center Programs...III-23 1$75
   Table 33: Number of Transplant Center Programs for the Years 1990, 1997 and 2000 (includes corresponding Graph/Chart)...III-24

Table 34: Average Number of Transplants Per Program for the Years 1990, 1997 and 2000 (includes corresponding Graph/Chart)...III-24
Strategic Developments...III-24
6$900
   Select Players...III-30
Abiomed Inc...III-30
1$75
   Arbios Systems Inc....III-31
Arrow International, Inc....III-31
1$75
   CryoLife, Inc....III-32
Exactech, Inc....III-32
1$75
   Genzyme Corporation...III-33
Jarvik Heart Inc....III-33
LifeCell Corporation...III-33
1$75
   Medtronic Inc...III-34
MicroMed Cardiovascular, Inc....III-34
1$75
   Organogenesis Inc...III-35
Forticell Bioscience, Inc....III-35
SynCardia Systems...III-35
Thoratec Corporation...III-35
1$75
   WorldHeart Corporation...III-361$75
   B. Market Analytics...III-37
Table 35: US Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type – Heart, Kidney, Liver, Pancreas, Lung and Intestine Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2012 (includes corresponding Graph/Chart)...III-37
1$200
   Table 36: US 10-Year Perspective for Organ Transplantation by Organ Type – Percentage Breakdown of Dollar Sales for Heart, Kidney, Liver, Pancreas, Lung and Intestine Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...III-381$200
   Table 37: US Recent Past, Current & Future Market Analysis for Tissue Transplantation by Tissue Type – Cornea, Heart Valves and Skin Grafts Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2012 (includes corresponding Graph/Chart)...III-39

Table 38: US 10-Year Perspective for Tissue Transplantation by Tissue Type – Percentage Breakdown of Dollar Sales for Cornea, Heart Valves and Skin Grafts Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...III-39
1$200
   Table 39: US Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type – Heart, Kidney, Liver, Pancreas, Lung and Intestine Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...III-401$200
   Table 40: US 10-Year Perspective for Organ Transplantation by Organ Type – Percentage Breakdown of Number of Procedures for Heart, Kidney, Liver, Pancreas, Lung and Intestine Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...III-411$200
   Table 41: US Recent Past, Current & Future Market Analysis for Tissue Transplantation by Tissue Type – Cornea, Heart Valves, Skin Grafts, Vascular Grafts, Bone Marrow and Bone Grafts Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...III-42

Table 42: US 10-Year Perspective for Tissue Transplantation by Tissue Type – Percentage Breakdown of Number of Procedures for Cornea, Heart Valves, Skin Grafts, Vascular Grafts, Bone Marrow and Bone Grafts Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...III-42
1$200
   Table 43: US Recent Past, Current & Future Market Analysis for Bone Graft Transplantation by Graft Type – Autologous Graft, Allograft and Other Materials Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...III-43

Table 44: US 10-Year Perspective for Bone Graft Transplantation by Graft Type – Percentage Breakdown of Number of Procedures for Autologous Graft, Allograft and Other Materials Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) (includes corresponding Graph/Chart)...III-43
1$200
   Table 45: US Recent Past, Current & Future Market Analysis for Bone Graft Transplantation by Application – General Orthopedics, Spinal Fusions and Cranio/Maxillofacial Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...III-44

Table 46: US 10-Year Perspective for Bone Graft Transplantation by Application – Percentage Breakdown of Number of Procedures for General Orthopedics, Spinal Fusions and Cranio/Maxillofacial Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...III-44
1$200
  2. Canada...III-454 $475  
   A. Market Analysis...III-45
Current and Future Analysis...III-45
Canadians More Receptive to Organ Transplants...III-45
Waiting List...III-45
1$75
   Table 47: Canadian Patients (Active and Inactive) on Waiting List by Organ Type for 2005 & 2006 (includes corresponding Graph/Chart)...III-46
Organ Donation...III-46
Success Rate of Organ Transplants...III-46
Table 48: Success Rate of Organ Transplants After 1-Year (includes corresponding Graph/Chart)...III-46
Strategic Development...III-46
1$200
   B. Market Analytics...III-47
Table 49: Canadian Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type – Heart, Kidney, Liver, Pancreas and Lung Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...III-47
1$200
   Table 50: Canadian 10-Year Perspective for Organ Transplantation by Organ Type – Percentage Breakdown of Number of Procedures for Heart, Kidney, Liver, Pancreas and Lung Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...III-48
1$200
  3. Europe...III-498 $850  
   A. Market Analysis...III-49
Current and Future Analysis...III-49
Italy ...III-49
Surge in Organ Transplants...III-49
The United Kingdom...III-49
Organ and Tissue Transplantation in the UK...III-49
Table 51: UK Organ Transplantations for the Years 2003 and 2004 (includes corresponding Graph/Chart)...III-49
1$200
   Table 52: Waiting List (Active and Inactive) by Organ Type in the UK for the Years 2003 and 2004 (includes corresponding Graph/Chart)...III-50
Kidney Transplantation...III-50
Waiting List...III-50
Categorized by Race...III-50
Categorized by Age and Sex...III-50
Donors and Transplantation Recipients...III-50
1$200
   Categorized by Race...III-51
Categorized by Age and Gender...III-51
Pancreas Transplantation...III-51
Waiting List...III-51
Categorized by Race...III-51
Categorized by Age and Gender...III-51
Donors and Transplantations...III-51
Categorized by Race...III-51
Categorized by Age and Gender...III-51
1$75
   Lung Transplant Record Numbers Boasts of Lung Power...III-52
Bladder Transplantation A Roaring Success...III-52
Russia...III-52
Organ Transplantations Show a Downward Trend in Russia...III-52
Turkey...III-52
Akdeniz University – A World-Renowned Transplantation Center...III-52
1$75
   Strategic Developments...III-531$75
   Select Players...III-54
Fresenius Medical Care AG & Co. KGaA (Germany)...III-54
Gambro AB (Sweden)...III-54
1$75
   B. Market Analytics...III-55
Table 53: European Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type – Heart, Kidney, Liver, Pancreas and Lung Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...III-55
1$200
   Table 54: European 10-Year Perspective for Organ Transplantation by Organ Type – Percentage Breakdown of Number of Procedures for Heart, Kidney, Liver, Pancreas and Lung Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...III-56
1$200
  4. Asia...III-5710 $775  
   A. Market Analysis...III-57
Current & Future Analysis...III-57
Australia...III-57
Australia Registers Highest Success Rate in Transplantation...III-57
Kidney Transplantation Snapshots...III-57
Organ Donor Register...III-57
1$75
   China...III-58
Organ Transplantations in China...III-58
Transplantation Tourism in China...III-58
Low Transplant Success Rate Due to Unskilled Professionals...III-58
Cost Effective Transplant Procedures Lure Foreign Patients...III-58
1$75
   Illegal Activities for Harvesting Organs in China...III-59
Regulations on Organ Transplantation...III-59
1$75
   Regulations on Brain Death...III-60
India...III-60
Overview of Renal Transplantation...III-60
Transplantation Expenses in India...III-60
Indian Government to amend Organ Transplantation Rules...III-60
1$75
   Singapore...III-61
Awareness Programs to Increase Living Kidney Donations in Singapore...III-61
Taiwan...III-61
Taiwan Competes with the US in Kidney and Liver Transplant Survival Rates...III-61
Strategic Developments...III-61
3$225
   Select Players...III-64
Terumo Corporation (Japan)...III-64
Ventracor Limited (Australia)...III-64
1$75
   B. Market Analytics...III-65
Table 55: Asia Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type – Heart, Kidney, Liver, Pancreas and Lung Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...III-65
1$200
   Table 56: Asia 10-Year Perspective for Organ Transplantation by Organ Type – Percentage Breakdown of Number of Procedures for Heart, Kidney, Liver, Pancreas and Lung Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...III-66
1$200
  5. Latin America...III-672 $325  
   A. Market Analysis...III-67
Current & Future Analysis...III-67
Brazil – A Major Transplant Market...III-67
B. Market Analytics...III-67
Table 57: Latin America Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type – Heart, Kidney, Liver, Pancreas and Lung Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...III-67
1$200
   Table 58: Latin America 10-Year Perspective for Organ Transplantation by Organ Type – Percentage Breakdown of Number of Procedures for Heart, Kidney, Liver, Pancreas and Lung Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...III-68
1$200
  6. Rest of World...III-693 $475  
   A. Market Analysis...III-69
Current & Future Analysis...III-69
Kuwait – A Rapidly Emerging ‘Third World’ Country in Organ Transplants...III-69
Strategic Development...III-69
1$75
   B. Market Analytics...III-70
Table 59: Rest of World Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type – Heart, Kidney, Liver, Pancreas and Lung Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart)...III-70
1$200
   Table 60: Rest of World 10-Year Perspective for Organ Transplantation by Organ Type – Percentage Breakdown of Number of Procedures for Heart, Kidney, Liver, Pancreas and Lung Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart)...III-711$200
IV. COMPETITIVE LANDSCAPE 247$995
  
Total Companies Profiled: 77 (including Divisions/Subsidiaries - 91 )

Region/Country                 Players

The United States                61
Canada                            2  
Japan                            10 
Europe                           16 
     France                       1 
     Germany                      6 
     The United Kingdom           2 
     Italy                        3
     Rest of Europe               4 
Asia-Pacific (Excluding Japan)    1 
Middle East                       1
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.